Recce Pharmaceuticals Ltd News

Recce Pharmaceuticals Ltd: Patient Dosing Complete in Phase II ABSSSI Trial of R327G

Jan 21 06:57

Recce Pharmaceuticals Ltd: Regulatory Approval for Registrational Phase 3 R327G Trial

Dec 9, 2024 06:05

Recce Pharmaceuticals Ltd: Trading Halt

Dec 5, 2024 06:21

Recce Pharmaceuticals Ltd: Presentation - Ord Minnett Biotech & MedTech Conference

Nov 28, 2024 09:42

Recce Pharmaceuticals Ltd: Australia Patent Granted for RECCE Anti-Infectives

Nov 26, 2024 05:37

Recce Pharmaceuticals Ltd: Change of Director's Interest Notices

Nov 21, 2024 16:31

Recce Pharmaceuticals Ltd: Notification regarding unquoted securities - RCE

Nov 21, 2024 16:21

Recce Pharmaceuticals Ltd: AUD $6.75m R&D Rebate Approved

Nov 14, 2024 07:38

Recce Pharmaceuticals Ltd: Notification regarding unquoted securities - RCE

Nov 13, 2024 14:14

Recce Pharmaceuticals Ltd: Ethics Approval for Registrational Ph3 R327G Clinical Trial

Nov 11, 2024 06:16

Recce Pharmaceuticals Ltd: Constitution

Nov 6, 2024 14:59

Recce Pharmaceuticals Ltd: Results of Special General Meeting

Nov 6, 2024 14:45

Recce Pharmaceuticals Ltd: Results of Annual General Meeting

Nov 6, 2024 14:33

Recce Pharmaceuticals Ltd: AGM Presentation

Nov 6, 2024 06:53

Recce Pharmaceuticals Ltd: Phase II ABSSSI Clinical Trial Advances to Final Stages

Nov 5, 2024 07:12

Recce Pharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Oct 31, 2024 15:20

Recce Pharmaceuticals Ltd: Efficacy Data & Approval to Continue Ph II ABSSSI Trial

Oct 28, 2024 06:44

Recce Pharmaceuticals Ltd: Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway

Oct 9, 2024 06:07

Recce Pharmaceuticals Ltd: Notice of Special General Meeting/Proxy Form

Oct 8, 2024 09:59

Recce Pharmaceuticals Ltd: Notice of Annual General Meeting/Proxy Form

Oct 8, 2024 09:57